New therapy for aggressive cancer approved abroad; German patients face delays

A novel medication for the most aggressive form of cancer is being hailed as a breakthrough, but availability in Germany is delayed, creating a race against time for patients. The specific cancer type and drug are not named in the source, and regulatory approval status in Germany is unclear. This matters because it highlights cross-border disparities in access to cutting-edge treatments.